Short Interest in Vaccinex, Inc. (NASDAQ:VCNX) Grows By 269.6%

Vaccinex, Inc. (NASDAQ:VCNX) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 127,500 shares, an increase of 269.6% from the October 15th total of 34,500 shares. Based on an average trading volume of 92,300 shares, the short-interest ratio is presently 1.4 days. Approximately 9.1% of the shares of the company are short sold.

Vaccinex Stock Performance

Shares of Vaccinex stock traded up $0.13 during trading hours on Tuesday, reaching $3.35. The company’s stock had a trading volume of 18,399 shares, compared to its average volume of 55,236. Vaccinex has a one year low of $1.39 and a one year high of $13.16. The company’s 50 day simple moving average is $3.72 and its 200 day simple moving average is $5.22. The stock has a market cap of $5.79 million, a P/E ratio of -0.05 and a beta of 0.98.

Vaccinex (NASDAQ:VCNX) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($3.10) earnings per share for the quarter. The company had revenue of $0.23 million for the quarter.

Institutional Trading of Vaccinex

A hedge fund recently raised its stake in Vaccinex stock. AIGH Capital Management LLC boosted its stake in Vaccinex, Inc. (NASDAQ:VCNX) by 86.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 108,958 shares of the company’s stock after buying an additional 50,593 shares during the period. AIGH Capital Management LLC owned 6.90% of Vaccinex worth $707,000 as of its most recent SEC filing. 50.11% of the stock is currently owned by hedge funds and other institutional investors.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.